Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Survivorship
Erschienen in: Journal of Cancer Survivorship 1/2008

01.03.2008

Long term physical sequelae after adult-onset cancer

verfasst von: Sophie D. Fosså, Rena Vassilopoulou-Sellin, Alv A. Dahl

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

With two thirds of cancer patients living for at least 5 years, clinical research has increasingly focused on the long-term health of cancer survivors. Contrary to the amount of knowledge on long-term consequences observations on late effects after childhood cancer in adult-onset cancer are sparse. Only limited literature is available recommending guidelines for long-term follow-up of cancer patients and their implementation in the delivery of health care.

Methods

In this review we summarize updated knowledge on the most frequent physical long-term effects after adult-onset cancer, and we discuss how these findings can be implemented in life-long follow-up programs of cancer survivors.

Results

Second cancer, cardiovascular disorders and gonadal dysfunction are the most common physical late effects along with fatigue. Common age-related co-morbidity reduces physical function in long-term cancer survivors.

Conclusions

Cancer survivors have to be informed about their risk of late effects, and how to prevent them by life style adjustments and, if indicated, regular health care visits. Studies on late effects after cancer treatment should be combined with translational research in order to improve our understanding of pathophysiological mechanisms of long-term effects. The effectiveness of therapeutic interventions for reduction of these treatment sequelae in long-term survivors need to be investigated in randomized trials. Guidelines for life-long follow-up of cancer survivors should be established and will form the first step is the design of an individual life-long cancer survivor care plan.
Literatur
1.
2.
3.
4.
5.
6.
Institute of Medicine and National Research Council. Cancer survivors in: from cancer patient to cancer survivor. In: Hewett M, Greenfield S, Stovall E, editors. Lost in transition. Washington DC: The National Academic Press; 2005. pp. 23–65.
7.
Skinner R, Wallace WHB, Levitt GA, on behalf of the UK Children’s Cancer Study Group (UKCCSG), Late Effects Group (LEG). Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol 2006;7:489–98.
8.
Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355(15):1572–82.PubMedCrossRef
9.
Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer 2003;104(4):488–95.PubMedCrossRef
10.
Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 2003;58(1):82–91.PubMed
11.
Nord C, Mykletun A, Thorsen L, Bjøro T, Fosså SD. Self-reported health and use of health care services in long-term cancer survivors. Int J Cancer 2005;114(2):307–16.PubMedCrossRef
12.
Rao AV, Denmark-Wahnefried W. The older cancer survivor. Crit Rev Oncol/Hematol 2006;60(2):131–43.CrossRef
13.
Deimling GT, Kahana B, Bowman KF, Schaefer ML. Cancer survivorship and psychological distress in later life. Psychooncology 2002;11(6):479–94.PubMedCrossRef
14.
Garman KS, Pieper CF, Seo P, Cohen HJ. Function in elderly cancer survivors depends on comorbidities. J Gerontol A Biol Sci Med Sci 2003;58(12):1119–24.
15.
Rowland JH, Yancik R. Cancer survivorship: the interface of aging, comorbidity, and quality care. J Nat Cancer Inst 2006;98(8):504–5.PubMed
16.
Ganz PA. Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer 2003;39(15):2136–41.PubMedCrossRef
17.
Aziz NA, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunities. Semin Radiat Oncol 2003;13:248–66.PubMedCrossRef
18.
Ayanian JZ, Jacobsen PB. Enhancing research on cancer survivors. J Clin Oncol 2006;24(32):5149–53.PubMedCrossRef
19.
Tichelli A and Socié G. Considerations for adult cancer survivors. Hematology Am Soc Hematol Educ Program 2005;516–22.
20.
Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 2007;25(12):1489–97.PubMedCrossRef
21.
Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int J Cancer 2001;93(2):155–61.PubMedCrossRef
22.
Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomark Prev 2006;15(11):2020–6.CrossRef
23.
Oosterhuis JW, Looijenga LHJ. Current views on the pathogenesis of testicular germ cell tumours and perspectives for future research: highlights of the 5th Copenhagen workshop on carcinoma in situ and cancer of the testis. APMIS 2003;111(1):280–9.PubMedCrossRef
24.
Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2006;4(2):156–76.PubMed
25.
Ghelani D, Saliba R, de Lima M. Secondary malignancies after hematopoietic stem cell transplantation. Crit Rev Oncol/Hematol 2005;56(1):115–26.CrossRef
26.
Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;5(12):943–55.PubMedCrossRef
27.
Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, Matthews J, Foot NJ, Lister TA, Young BD, Rohatiner AZ. Genetic susceptibility to Hodgkin’s disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. Ann Oncol 2002;13(Suppl 1):40–3.PubMed
28.
Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97(18):1354–65.PubMed
29.
Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290(4):465–75.PubMedCrossRef
30.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL, et al. Effects of Tamoxifen vs Raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006;295(23):2727–41.PubMedCrossRef
31.
Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005;32(2):71–80.CrossRef
32.
Hooning MJ, Botma A, Aleman BMP, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99(5):365–75.PubMedCrossRef
33.
Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003;4(9):529–36.PubMedCrossRef
34.
Friedman DL, Constine LS. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 2006;4(3):249–57.PubMed
35.
Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van’t Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109(5):1878–86.PubMedCrossRef
36.
Van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodriqus PT, Schimmel EC, Aleman BM, van Leeuwen FE. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24(3):467–75.PubMedCrossRef
37.
Dewar JA. Postmastectomy Radiotherapy. Clin Oncol 2006;18(3):185–90.CrossRef
38.
Fosså SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007;99(7):533–44.PubMedCrossRef
39.
Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of most promising strategies. Br J Haematol 2005;131(5):561–78.PubMedCrossRef
40.
Ewer MS, Martin FJ, Henderson IC, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31(6):161–81.PubMedCrossRef
41.
Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev 2002;28(4):195–214.PubMedCrossRef
42.
Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21(8):1513–23.PubMedCrossRef
43.
Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005;23(22):4980–90.PubMedCrossRef
44.
Fosså SD, Aass N, Winderen M, Börmer OP, Olsen DR. Long-term renal function after treatment for malignant germ cell tumours. Ann Oncol 2003;13(2):222–8.CrossRef
45.
Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 2006;106(4):751–8.PubMedCrossRef
46.
Pheilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000;18(7):1570–93.
47.
Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):287–95.PubMedCrossRef
48.
Iversen P, Johansson JE, Lodding P, Kylmala T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong T, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40(6):441–52.PubMedCrossRef
49.
Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AL, Schlichting E, Lien EA, Ofjord ES, Paolini J, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23(22):5126–37.PubMedCrossRef
50.
Jonat W. Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation. Breast Cancer Res Treat 2002;75:23–6.CrossRef
51.
Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelver H, Leiter C, Farkas A, Spitz IM. Reversibility of androgen deprivation therapy in patients with prostate cancer. J Urol 2005;173(3):784–9.PubMedCrossRef
52.
Howell SJ, Shalet SM. Effect of cancer therapy on pituitary-testicular axis. Int J Androl 2002;25(5):269–76.PubMedCrossRef
53.
Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18(2):241–8.PubMedCrossRef
54.
Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979–83.PubMedCrossRef
55.
Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353(1):64–73.PubMedCrossRef
56.
Haukvik UK, Dieset I, Bjoro T, Holte H, Fossa SD. Treatment-related premature ovarian failure as a long-term complication after Hodgkin’s lymphoma. Ann Oncol 2006;17(9):1428–33.PubMedCrossRef
57.
Magelssen H, Brydoy M, Fossa SD. The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract Urol 2006;3(6):312–22.PubMedCrossRef
58.
Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62(3):738–44.PubMed
59.
Fosså SD, Magelssen H, Melve K, Jacobsen AB, Langmark F, Skjaerven R. Parenthood in survivors after adulthood cancer and perinatal health in their offspring: a preliminary report. J Natl Cancer Inst Monographs 2005;34:77–82.PubMedCrossRef
60.
Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005;97(21):1580–8.PubMed
61.
Kiserud CE, Fosså A, Holte H, Fosså SD. Post-treatment parenthood Hodgkin’s lymphoma survivors. Br J Cancer 2007;96(9):1442–9.PubMed
62.
Kumar N, Allen KA, Riccardi D, Bercu BB, Cantor A, Minton S, Balducci L, Jacobsen PB. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit? Breast Cancer Res Treat 2004;83(2):149–59.PubMedCrossRef
63.
Agha A, Sherlock M, Brennan S, O’Connor SA, O’Sullivan E, Rogers B, Faul C, Rawluk D, Tormey W, Thompson CJ. Hypothalamic-Pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab 2005;90(12):6355–60.PubMedCrossRef
64.
65.
Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 2005;66(5):83–94.PubMedCrossRef
66.
Potosky AL, Davis WW, Hoffman RM, Standford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate cancer Outcome Study. J Natl Cancer Inst 2004;96(18):1358–67.PubMed
67.
Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;41(4):427–33.PubMedCrossRef
68.
Armstrong CL, Gyato K, Awadalla AW, Lustiq R, Tochner ZA. A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol Rev 2004;14(1):65–86.PubMedCrossRef
69.
Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose Methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS Lymphoma. J Clin Oncol 2006;24(28):4570–4.PubMedCrossRef
70.
Galecki J, Hicer-Grzenkowicz J, Grudzien-Kowalska M, Michalska T, Zalucki W. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer – a review. Acta Oncol 2006;45(3):280–4.PubMedCrossRef
71.
Mykletun A, Dahl AA, Haaland CF, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Side-effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 2005;23(13):3061–8.PubMedCrossRef
72.
Oldenburg J, Kraggerud Sm, Cvancarova M, Lothe RA, Fosså SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25(6):708–14.PubMedCrossRef
73.
Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22(11):2233–9.PubMedCrossRef
74.
Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B. Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61(2):318–28.PubMed
75.
Stensvold E, Aass N, Gladhaug I, Stenwig AE, Claussen OP, Fossa SD. Erroneous diagnosis of pancreatic cancer after radiotherapy of testicular cancer. Eur J Surg Oncol 2004;30(3):352–5.PubMedCrossRef
76.
Maduro JH, Pras E, Willemse PHB, de Vries EGE. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 2003;29:471–88.PubMedCrossRef
77.
Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, Williams C, Collingwood M. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005;20 (3):Review.
78.
Lundby L, Krogh K, Jensen VJ, Gandrup P, Qvist N, Overgaard J, Laurberg S. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum 2005;45(7):1343–9.CrossRef
79.
Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8(6):475–87.PubMedCrossRef
80.
Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ. ASCO Cancer Survivorship Expert Panel. J Clin Oncol 2007;25(25):3991–4008.PubMedCrossRef
81.
Working party of the British Committee for Standards in hematology, clinical hematology task force. Guidelines for prevention and treatment of infection in post splenectomy patients or those with dysfunction spleen.. Br Med J 1996;312(7028):430–4.
82.
Webb CW, Crowell K, Cravens D. Clinical inquiries. Which vaccinations are indicated after splenectomy? J Fam Pract 2006;55(8):711–2.PubMed
83.
Winquist EW, Bauman GS, Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol 2001;24(6):603–6.PubMedCrossRef
84.
Sciubba JJ, Goldenberg D. Oral complications of radiotherapy. Lancet Oncol 2006;7(2):75–83.CrossRef
85.
Gordon KG, Char DH, Sagerman RH. Late effects of radiation on the eye and ocular adnexa. Int J Radiat Oncol Biol Phys 1995;31(5):1123–39.PubMed
86.
Stava C, Beck M, Vassilopoulou-Sellin R. Cataracts among cancer survivors. Am J Clin Oncol 2005;28(6):603–8.PubMedCrossRef
87.
Ness KK, Wall MM, Oakes JM, Robinson LL, Gurney JG. Physical performance limitations and participation restrictions among cancer survivors: a population-based study. Ann Epidemiol 2006;16(3):197–205.PubMedCrossRef
88.
Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 2003;58(1):82–91.PubMed
89.
Sweeney C, Schmitz KH, Lazovich D, Virnig BA, Wallace RB, Folsom AR. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst 2006;98(8):521–9.PubMedCrossRef
90.
Fosså SD, Hess SL, Dahl AA, Hjermstad MJ, Veenstra M. Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta Oncol 2007;46(4):452–61.PubMedCrossRef
91.
Ruffer JU, Fletchner H, Tralls P, Josting A, Sieber M, Lathan B, Diehl V. Fatigue in long-term survivors of Hodgkin’s lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003;39(15):2179–86.PubMedCrossRef
92.
Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer42(3):327–33.
93.
Ng AK, Recklitis C, Neuberg D, Chakrabarti S, Silver B, Diller LA. Comparison between long-term survivors of Hodgkin’s disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol 2005;16(12):1949–55.PubMedCrossRef
94.
Kato K, Sullivan PF, Evengård B, Pedersen NL. Premorbid predictors of chronic fatigue. Arch Gen Psychiatry 2006;63(11):1267–72.PubMedCrossRef
95.
Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun 2007;21(3):251–8.PubMedCrossRef
96.
Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ, American Society of Clinical Oncology. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J Clin Oncol 2006;24(1):190–205.PubMedCrossRef
97.
Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol 2006;24(32):5117–24.PubMedCrossRef
98.
Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol 2006;24(32):5112–6.PubMedCrossRef
99.
Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting health and physical function among cancer survivors: potential for prevention and questions that remain. J Clin Oncol 2006;24(32):5125–31.PubMedCrossRef
100.
van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MWJ, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BMP, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25(28):4370–8.PubMedCrossRef
101.
Ralleigh G, Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin’s disease. Clin Radiol 2004;59(8):647–50.PubMedCrossRef
Metadaten
Titel
Long term physical sequelae after adult-onset cancer
verfasst von
Sophie D. Fosså
Rena Vassilopoulou-Sellin
Alv A. Dahl
Publikationsdatum
01.03.2008
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2008
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-007-0039-5

Weitere Artikel der Ausgabe 1/2008

Journal of Cancer Survivorship 1/2008 Zur Ausgabe

OriginalPaper

The UK Expert Patients Program: Lessons learned and implications for cancer survivors’ self-care support programs

OriginalPaper

Non-cancer adverse health conditions and perceived health and function among cancer survivors participating in a community-based cohort study in Washington County, Maryland

OriginalPaper

What makes cancer survivor stories work? An empirical study among African American women

OriginalPaper

Barriers to pain assessment and management in cancer survivorship

News

Impacting the lives of cancer survivors: reflections on the first year of the journal of cancer survivorship: research and practice

OriginalPaper

Survivorship issues following treatment completion—results from focus groups with Australian cancer survivors and health professionals

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise